Mobile

A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Potentia...

Update Il y a 4 ans
Reference: EUCTR2007-003134-42

A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Potentials (ERPs) in Patients with Idiopathic Parkinson’s Disease and End-of-Dose Wearing Off

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this study is to evaluate the effects of Stalevo versus immediaterelease carbidopa/levodopa on the latency of the P300 component of ERPs at the midline electrode site Cz, 4 hours post-levodopa administration (ERP4hrs) in patients with idiopathic PD.

Inclusion criteria

  • Idiopathic Parkinson’s disease and end-of-dose wearing off

Links